Published in J Clin Epidemiol on January 24, 2007
Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes (2009) 2.05
Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902). Cancer (2015) 1.48
Patient reported outcomes: looking beyond the label claim. Health Qual Life Outcomes (2010) 1.35
Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia (2013) 0.88
Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits. Patient Prefer Adherence (2014) 0.80
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol (2011) 5.67
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol (2004) 3.42
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med (2015) 3.18
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol (2004) 3.02
Adaptive design methods in clinical trials - a review. Orphanet J Rare Dis (2008) 2.88
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood (2011) 2.82
Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol (2005) 2.68
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood (2006) 2.51
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood (2011) 2.37
Nuclear factor kappa B signaling regulates neuronal morphology and cocaine reward. J Neurosci (2009) 2.25
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol (2010) 2.24
Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol (2005) 2.17
The health-related quality of life and economic burden of constipation. Pharmacoeconomics (2005) 2.14
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. Am J Hematol (2015) 2.03
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res (2013) 2.02
Gastroparesis Cardinal Symptom Index (GCSI): development and validation of a patient reported assessment of severity of gastroparesis symptoms. Qual Life Res (2004) 1.88
Statistical inference for cancer trials with treatment switching. Stat Med (2005) 1.82
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol (2011) 1.81
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol (2013) 1.79
Risk factors for chronic constipation based on a general practice sample. Am J Gastroenterol (2003) 1.63
The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. Eur J Haematol (2010) 1.60
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol (2005) 1.56
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol (2012) 1.50
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica (2012) 1.47
Perceived benefits of sharing health data between people with epilepsy on an online platform. Epilepsy Behav (2011) 1.38
Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica (2008) 1.28
Cross-cultural development and validation of a patient self-administered questionnaire to assess quality of life in upper gastrointestinal disorders: the PAGI-QOL. Qual Life Res (2004) 1.26
Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood (2010) 1.26
Statistical consideration of adaptive methods in clinical development. J Biopharm Stat (2005) 1.25
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood (2013) 1.21
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica (2013) 1.19
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol (2013) 1.17
Core competencies for pharmaceutical physicians and drug development scientists. Front Pharmacol (2013) 1.15
Use of patient-reported sleep measures in clinical trials of pain treatment: a literature review and synthesis of current sleep measures and a conceptual model of sleep disturbance in pain. Clin Ther (2007) 1.12
Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J Clin Oncol (2012) 1.10
Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. J Clin Oncol (2006) 1.09
Defining minimally important change in QOLIE-31 scores: estimates from three placebo-controlled lacosamide trials in patients with partial-onset seizures. Epilepsy Behav (2012) 1.09
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood (2012) 1.07
Medical visits among adults with symptoms commonly associated with an overactive bladder. BJU Int (2006) 1.07
Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. Clin Pharmacokinet (2012) 1.06
Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain. Eur J Pain (2006) 1.06
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica (2008) 1.06
Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. Eur J Haematol (2012) 1.04
Lack of objective evidence of efficacy of laxatives in chronic constipation. Dig Dis Sci (2002) 1.02
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? Br J Haematol (2006) 1.02
Response to bortezomib and activation of osteoblasts in multiple myeloma. Clin Lymphoma Myeloma (2006) 1.01
Responsiveness and interpretation of a symptom severity index specific to upper gastrointestinal disorders. Clin Gastroenterol Hepatol (2004) 1.00
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood (2005) 0.99
A new measure of patient satisfaction with ocular hypotensive medications: the Treatment Satisfaction Survey for Intraocular Pressure (TSS-IOP). Health Qual Life Outcomes (2003) 0.99
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. Eur J Haematol (2011) 0.99
Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenet Genomics (2011) 0.98
A role for epsin N-terminal homology/AP180 N-terminal homology (ENTH/ANTH) domains in tubulin binding. J Biol Chem (2003) 0.97
A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. Clin Cancer Res (2007) 0.95
A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica (2010) 0.94
A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. Cancer Chemother Pharmacol (2008) 0.94
Plasma-deposited tetraglyme surfaces greatly reduce total blood protein adsorption, contact activation, platelet adhesion, platelet procoagulant activity, and in vitro thrombus deposition. J Biomed Mater Res A (2007) 0.94
A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res (2014) 0.92
Development and validation of an acceptability and satisfaction questionnaire for a contraceptive vaginal ring, NuvaRing. Pharmacoeconomics (2004) 0.92
European initiative towards quality standards in education and training for discovery, development and use of medicines. Eur J Pharm Sci (2011) 0.92
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am J Hematol (2015) 0.92
Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. Am J Hematol (2007) 0.92
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol (2008) 0.91
Health economics and nutrition: a review of published evidence. Nutr Rev (2012) 0.90
Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma (2014) 0.89
Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab. Clin Cancer Res (2013) 0.89
Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer. J Pain Symptom Manage (2008) 0.88
Responsiveness and interpretation of a quality of life questionnaire specific to upper gastrointestinal disorders. Clin Gastroenterol Hepatol (2004) 0.88
TRAF6-dependent NF-kB transcriptional activity during mouse development. Dev Dyn (2004) 0.88
The cost utility of autologous chondrocytes implantation using ChondroCelect® in symptomatic knee cartilage lesions in Belgium. Pharmacoeconomics (2010) 0.86
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens. Int J Gynecol Cancer (2012) 0.86
Psychometric evaluation of the functional assessment of HIV Infection (FAHI) questionnaire and its usefulness in clinical trials. Qual Life Res (2010) 0.85
Effects of etravirine versus placebo on health-related quality of life in treatment-experienced HIV patients as measured by the functional assessment of human immunodeficiency virus infection (FAHI) questionnaire in the DUET trials. HIV Clin Trials (2010) 0.85
Focal expression and final activity of matrix metalloproteinases may explain irregular dysfunctional endometrial bleeding. Am J Pathol (2004) 0.83
Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence. Pharmacoeconomics (2004) 0.82
Mapping MOS Sleep Scale scores to SF-6D utility index. Curr Med Res Opin (2007) 0.82
Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone. Curr Med Res Opin (2007) 0.82
Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma. Haematologica (2008) 0.81
A threshold regression mixture model for assessing treatment efficacy in a multiple myeloma clinical trial. J Biopharm Stat (2008) 0.81
Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma. Clin Pharmacokinet (2011) 0.80
Community subgroups in dyspepsia and their association with weight loss. Am J Gastroenterol (2008) 0.79
Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease. Pharmacoeconomics (2005) 0.79
Validation of the short-form REFLUX-QUAL (RQS), a gastro-esophageal reflux disease (GERD) specific quality of life questionnaire. Gastroenterol Clin Biol (2005) 0.79
Dose selection of siltuximab for multicentric Castleman's disease. Cancer Chemother Pharmacol (2015) 0.79
Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma. Cancer Chemother Pharmacol (2013) 0.78
Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective. J Opioid Manag (2011) 0.78
Recommended structure for reporting economic evaluation on pharmaceuticals in Belgium. Pharm World Sci (2002) 0.77
Psychometric properties of PedsQL generic core scales for children with functional constipation in the Netherlands. J Pediatr Gastroenterol Nutr (2014) 0.77
Healthcare resource use in advanced prostate cancer patients treated with docetaxel. J Med Econ (2012) 0.76